CR10663A - 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridina-2-carboxamida monohidrato - Google Patents

4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridina-2-carboxamida monohidrato

Info

Publication number
CR10663A
CR10663A CR10663A CR10663A CR10663A CR 10663 A CR10663 A CR 10663A CR 10663 A CR10663 A CR 10663A CR 10663 A CR10663 A CR 10663A CR 10663 A CR10663 A CR 10663A
Authority
CR
Costa Rica
Prior art keywords
fluorophenoxy
phenyl
amino
carboxamide
monohidrate
Prior art date
Application number
CR10663A
Other languages
English (en)
Inventor
Alfons Grunenberg
Juergen Stiehl
Katharina Tenbieg
Birgit Keil
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38972960&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10663(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CR10663A publication Critical patent/CR10663A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente invencion se refiere a 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-N-metilpiridina-2-carboxamida monohidrato, a procedimientos para su preparacion, a composiciones farmaceuticas que lo comprenden y a su uso en el combate de trastornos.
CR10663A 2006-10-11 2009-03-13 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridina-2-carboxamida monohidrato CR10663A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06021296 2006-10-11

Publications (1)

Publication Number Publication Date
CR10663A true CR10663A (es) 2009-07-31

Family

ID=38972960

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10663A CR10663A (es) 2006-10-11 2009-03-13 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridina-2-carboxamida monohidrato

Country Status (37)

Country Link
US (3) US9957232B2 (es)
EP (1) EP2097381B1 (es)
JP (1) JP5346293B2 (es)
KR (1) KR101418623B1 (es)
CN (1) CN101547903B (es)
AR (1) AR062927A1 (es)
AU (1) AU2007306716B2 (es)
BR (1) BRPI0719828B1 (es)
CA (1) CA2666170C (es)
CL (1) CL2007002930A1 (es)
CO (1) CO6150132A2 (es)
CR (1) CR10663A (es)
CY (1) CY1114637T1 (es)
DK (1) DK2097381T3 (es)
ES (1) ES2427358T3 (es)
GT (1) GT200900057A (es)
HN (1) HN2009000499A (es)
IL (1) IL197369A (es)
JO (1) JO3021B1 (es)
MA (1) MA30878B1 (es)
MX (1) MX2009002642A (es)
MY (1) MY152595A (es)
NZ (1) NZ576153A (es)
PA (1) PA8750301A1 (es)
PE (1) PE20081459A1 (es)
PL (1) PL2097381T3 (es)
PT (1) PT2097381E (es)
RU (1) RU2466992C2 (es)
SG (1) SG175584A1 (es)
SI (1) SI2097381T1 (es)
SV (1) SV2009003187A (es)
TN (1) TN2009000072A1 (es)
TW (1) TWI428322B (es)
UA (1) UA95984C2 (es)
UY (1) UY30633A1 (es)
WO (1) WO2008043446A1 (es)
ZA (1) ZA200902469B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1636585B2 (en) * 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
EP1663978B1 (en) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
DK1797038T3 (da) * 2004-09-29 2012-09-03 Bayer Pharma AG Termodynamisk stabil form af bay 43-9006-tosylat
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
EP2089363A1 (en) * 2006-11-14 2009-08-19 Bayer Schering Pharma Aktiengesellschaft Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]n-methylpyridine-2-carboxamide
CA2675980C (en) 2007-01-19 2016-06-21 Bayer Healthcare Llc Use of dast for treatment of cancers with acquired resistance to kit inhibitors
AR081060A1 (es) * 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
AU2015201426B2 (en) * 2010-04-15 2016-07-07 Bayer Healthcare Llc Process for the preparation of 4- {4-[({[4 -chloro-3 -(trifluoromethyl)-phenyl]amino} carbonyl)amino]-3-fluorophenoxy}-N-methylpyridine-2-carboxamide, its salts and monohydrate
CA2805874A1 (en) 2010-07-19 2012-01-26 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
US9381177B2 (en) 2010-10-01 2016-07-05 Bayer Intellectual Property Gmbh Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
KR20140048218A (ko) * 2011-06-28 2014-04-23 바이엘 헬스케어 엘엘씨 레고라페닙을 함유하는 국소 안과용 약학 조성물
AR092439A1 (es) 2012-09-06 2015-04-22 Bayer Healthcare Llc Composicion farmaceutica recubierta que contiene regorafenib
EP2900269B1 (en) 2012-09-25 2018-08-01 Bayer Pharma Aktiengesellschaft Combination of regorafenib and acetylsalicylic acid for treating colorectal cancer
UY35183A (es) 2012-12-21 2014-07-31 Bayer Healthcare Llc Composición farmacéutica oftalmológica tópica que contiene regorafenib
WO2015049698A2 (en) * 2013-10-04 2015-04-09 Hetero Research Foundation Process for regorafenib
CN103923000A (zh) * 2014-01-29 2014-07-16 苏州晶云药物科技有限公司 几种新晶型及其制备方法
CN104829523B (zh) * 2014-04-30 2017-10-31 药源药物化学（上海）有限公司 瑞戈非尼盐及其晶型、制备方法
WO2016005874A1 (en) 2014-07-09 2016-01-14 Shilpa Medicare Limited Process for the preparation of regorafenib and its crystalline forms
WO2016038590A1 (en) 2014-09-12 2016-03-17 Mylan Laboratories Ltd Process for the preparation of crystalline form i of regorafenib
CN104546776B (zh) * 2015-02-10 2017-08-22 杭州朱养心药业有限公司 瑞戈非尼片剂药物组合物和制法
CN105985287B (zh) * 2015-02-13 2018-07-17 上海京新生物医药有限公司 一种瑞戈非尼新晶型
CN107118153A (zh) * 2016-02-25 2017-09-01 石药集团中奇制药技术（石家庄）有限公司 一种瑞戈非尼一水合物晶型及其制备方法
CN105879049B (zh) * 2016-05-13 2019-03-26 浙江大学 一种瑞戈非尼与β-环糊精的包合物及其制备方法
CA3244313A1 (en) 2017-06-02 2025-06-13 Bayer Healthcare Llc Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
EP3861989A1 (en) 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
WO2021160708A1 (en) 2020-02-14 2021-08-19 Bayer Aktiengesellschaft Combination of regorafenib and msln-ttc for treating cancer
CN111995571B (zh) * 2020-08-07 2021-12-03 天津理工大学 一种瑞戈非尼与马来酸的共晶及其制备方法

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6705789A (es) 1967-03-08 1968-09-09
US4223153A (en) 1979-02-09 1980-09-16 Eli Lilly And Company Crystalline forms of N-2-(6-methoxy)benzothiazolyl N'-phenyl urea
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
NZ220764A (en) * 1986-07-02 1989-09-27 Shionogi & Co Crystalline form of 7beta((z)-2-(2-aminothiazol-4-yl)-4- carboxybut-2-enoylamino)-3-cephem-4-carboxylic acid and pharmaceutical compositions
US4835180A (en) * 1986-10-02 1989-05-30 Sterling Drug Inc. N-(ω-cyanoalkyl)aminophenols and use as inhibitors of lipoxygenase activity
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
CO4410190A1 (es) 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
US5629425A (en) * 1994-09-19 1997-05-13 Eli Lilly And Company Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
WO1997046526A1 (en) * 1996-06-07 1997-12-11 Eisai Co., Ltd. Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
JP2001500878A (ja) 1996-09-23 2001-01-23 イーライ・リリー・アンド・カンパニー オランザピン二水和物ｄ
US6187799B1 (en) * 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US6344476B1 (en) * 1997-05-23 2002-02-05 Bayer Corporation Inhibition of p38 kinase activity by aryl ureas
US20070244120A1 (en) * 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
US7517880B2 (en) * 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US20080300281A1 (en) * 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
US7329670B1 (en) * 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US20120046290A1 (en) * 1997-12-22 2012-02-23 Jacques Dumas Inhibition of p38 kinase activity using substituted heterocyclic ureas
US20080269265A1 (en) * 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
EP1158985B1 (en) * 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US7928239B2 (en) * 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US8124630B2 (en) * 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ME00275B (me) * 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN190389B (es) * 1999-07-14 2003-07-26 Ranbaxy Lab Ltd
EP1248869A2 (en) 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US7235576B1 (en) * 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2003047579A1 (en) * 2001-12-03 2003-06-12 Bayer Pharmaceuticals Corporation Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
US20030207872A1 (en) * 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928277B1 (en) * 2002-02-11 2011-04-19 Cox Jr Henry Wilmore Method for reducing contamination
SI1478358T1 (sl) * 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
WO2003068229A1 (en) * 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
ATE529406T1 (de) * 2002-02-11 2011-11-15 Bayer Healthcare Llc Aryl-harnstoffe als kinase inhibitoren
EP1504047B1 (en) * 2002-05-03 2007-12-12 Janssen Pharmaceutica N.V. Polymeric microemulsions
US7557129B2 (en) * 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
EP1636585B2 (en) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
EP1663978B1 (en) * 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
WO2005040100A1 (en) * 2003-10-15 2005-05-06 Bayer Healthcare Ag Tetrahydro-naphthalene and urea derivatives
TWI338004B (en) 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
EP2295426A1 (en) * 2004-04-30 2011-03-16 Bayer HealthCare, LLC Substituted pyrazolyl urea derivatives useful in the treatment of cancer
ATE395905T1 (de) * 2004-08-27 2008-06-15 Bayer Pharmaceuticals Corp Pharmazeutische zusammensetzungen in form fester dispersionen zur behandlung von krebs
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
DK1797038T3 (da) * 2004-09-29 2012-09-03 Bayer Pharma AG Termodynamisk stabil form af bay 43-9006-tosylat
EP1797037B1 (en) 2004-09-29 2014-12-17 Bayer HealthCare LLC Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenyoxy}n-methylpyridine-2-carboxamide
ATE482693T1 (de) * 2005-03-07 2010-10-15 Bayer Schering Pharma Ag Pharmazeutische zusammensetzung mit einem omega- carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs
MX2007014726A (es) 2005-05-27 2008-02-14 Bayer Healthcare Ag Tratamiento combinado que comprende un compuesto diarilurea y una pi3, akt cinasa o inhibidores mtor (rapamicina) para tratamiento de cancer.
CA2609387A1 (en) * 2005-05-27 2006-11-30 Bayer Healthcare Ag Combination therapy comprising diaryl ureas for treating diseases
WO2007047955A2 (en) * 2005-10-21 2007-04-26 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy
US20090215835A1 (en) * 2005-10-31 2009-08-27 Scott Wilhelm Treatment of cancer with sorafenib
US8329408B2 (en) * 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
JP2009513707A (ja) * 2005-10-31 2009-04-02 バイエル ヘルスケア リミティド ライアビリティ カンパニー ジアリールウレア及び併用剤
US20080311601A1 (en) * 2005-11-02 2008-12-18 Elting James J Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy
BRPI0618522A2 (pt) * 2005-11-10 2011-09-06 Bayer Healthcare Ag diaril uréia para o tratamento de hipertensão pulmonar
ATE493986T1 (de) * 2005-11-10 2011-01-15 Bayer Schering Pharma Ag Diarylharnstoffe zur behandlung von pulmonaler hypertonie
BRPI0618597A2 (pt) * 2005-11-14 2011-09-06 Bayer Healthcare Llc métodos de predição e prognóstico de cáncer e método de monitoramento de terapia contra o cáncer
JP2009515978A (ja) * 2005-11-14 2009-04-16 バイエル ヘルスケア エルエルシー Ｋｉｔ阻害剤に対する獲得耐性を伴う癌の治療
US20110195110A1 (en) * 2005-12-01 2011-08-11 Roger Smith Urea compounds useful in the treatment of cancer
CA2633417A1 (en) * 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryl ureas for treating virus infections
US20090227637A1 (en) * 2005-12-15 2009-09-10 Olaf Weber Diaryl ureas for treating virus infections
US20100129321A1 (en) * 2005-12-15 2010-05-27 Bayer Healthcare Llc Diaryl urea for treating virus infections
WO2007075650A2 (en) * 2005-12-21 2007-07-05 Bayer Healthcare Ag Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
EP2094268A2 (en) * 2006-05-26 2009-09-02 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
US20100063112A1 (en) * 2006-11-09 2010-03-11 Bayer Schering Pharma Aktiengesellschaft Polymorph iii of 4-[4-(amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
EP2089363A1 (en) * 2006-11-14 2009-08-19 Bayer Schering Pharma Aktiengesellschaft Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]n-methylpyridine-2-carboxamide
JP2010514692A (ja) * 2006-12-20 2010-05-06 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌の治療に有用なヒドロキシメチルフェニルピラゾリル尿素化合物
AU2007336873A1 (en) * 2006-12-20 2008-07-03 Bayer Healthcare Llc 4-{4-[({3-tert-Butyl-1-[3-(hydroxymethyl) phenyl]-1H-pyrazol-5-yl } carbamoyl)-amino] -3-fluorophenoxy} -N-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer
JP2010516692A (ja) * 2007-01-19 2010-05-20 バイエル・ヘルスケア・エルエルシー 化学療法剤に対し抵抗性を有する癌の処置
CA2675980C (en) * 2007-01-19 2016-06-21 Bayer Healthcare Llc Use of dast for treatment of cancers with acquired resistance to kit inhibitors
EP2231612A1 (en) * 2008-01-17 2010-09-29 Sicor, Inc. Polymorph form iii of sorafenib tosylate, sorafenib tosylate methanol solvate and sorafenib tosylate ethanol solvate, and processes for preparation thereof
JP2011525503A (ja) * 2008-06-25 2011-09-22 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 心不全を処置するためのジアリールウレア
JP5439494B2 (ja) * 2008-10-21 2014-03-12 バイエル ヘルスケア エルエルシー 肝細胞癌と関連するシグネチャ遺伝子の同定
CA2775296A1 (en) * 2009-09-24 2011-03-31 Ranbaxy Laboratories Limited Polymorphs of sorafenib acid addition salts
WO2011058522A1 (en) * 2009-11-12 2011-05-19 Ranbaxy Laboratories Limited Sorafenib ethylsulfonate salt, process for preparation and use
WO2011146725A1 (en) 2010-05-19 2011-11-24 Bayer Healthcare Llc Biomarkers for a multikinase inhibitor
CA2805874A1 (en) 2010-07-19 2012-01-26 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions

Also Published As

Publication number Publication date
HN2009000499A (es) 2012-03-07
CY1114637T1 (el) 2016-10-05
CO6150132A2 (es) 2010-04-20
KR101418623B1 (ko) 2014-07-14
US20140315958A1 (en) 2014-10-23
CL2007002930A1 (es) 2008-04-04
MX2009002642A (es) 2009-05-28
HK1136287A1 (en) 2010-06-25
TWI428322B (zh) 2014-03-01
UY30633A1 (es) 2008-05-31
DK2097381T3 (da) 2013-09-23
IL197369A (en) 2015-06-30
CA2666170A1 (en) 2008-04-17
PT2097381E (pt) 2013-09-17
ZA200902469B (en) 2010-06-30
ES2427358T3 (es) 2013-10-30
SI2097381T1 (sl) 2013-11-29
WO2008043446A1 (en) 2008-04-17
JP5346293B2 (ja) 2013-11-20
IL197369A0 (en) 2009-12-24
PL2097381T3 (pl) 2013-11-29
JP2010505888A (ja) 2010-02-25
SV2009003187A (es) 2009-11-26
RU2009117388A (ru) 2010-11-20
BRPI0719828A2 (pt) 2014-02-04
CA2666170C (en) 2016-05-24
CN101547903A (zh) 2009-09-30
AU2007306716B2 (en) 2013-06-20
MA30878B1 (fr) 2009-11-02
TN2009000072A1 (en) 2010-08-19
KR20090061043A (ko) 2009-06-15
NZ576153A (en) 2012-02-24
JO3021B1 (ar) 2016-09-05
GT200900057A (es) 2009-12-09
AU2007306716A1 (en) 2008-04-17
PE20081459A1 (es) 2008-12-18
UA95984C2 (en) 2011-09-26
TW200831465A (en) 2008-08-01
RU2466992C2 (ru) 2012-11-20
AR062927A1 (es) 2008-12-17
US9957232B2 (en) 2018-05-01
SG175584A1 (en) 2011-11-28
US20180194730A1 (en) 2018-07-12
PA8750301A1 (es) 2009-01-23
MY152595A (en) 2014-10-31
EP2097381A1 (en) 2009-09-09
US20100173953A1 (en) 2010-07-08
CN101547903B (zh) 2014-01-15
EP2097381B1 (en) 2013-06-19
BRPI0719828B1 (pt) 2022-05-17

Similar Documents

Publication Publication Date Title
CR10663A (es) 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridina-2-carboxamida monohidrato
CU20070068A7 (es) Forma termodinámicamente estable de una sal tosilato
UY30319A1 (es) Formulaciones de inhibidores de dpp iv
CL2007002446A1 (es) Compuestos derivados de morfolino pirimidina; composicion farmaceutica; y su uso para preparar un medicamento para producir un efecto antiproliferante.
BRPI0820665A2 (pt) compostos de peptidil nitrilas, processos para fabricação dos mesmos, composição farmacêutica, combinação e uso de ditos compostos
CL2007003100A1 (es) Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria.
CL2007001915A1 (es) Compuesto cristalino de 6-[4-cloro-3-(4-etoxibencil)fenil]tetrahidropiran-2,3,4,5,-tetraol; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y su uso para preparar un medicamento para tratar diabetes, dislipidemia, obesidad, entre otras.
EA201200550A1 (ru) Фармацевтические композиции, включающие bi-1356 и метформин
CY1117524T1 (el) Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες
CL2007002107A1 (es) Compuestos derivados de bencil piperidin-1-il amina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hiperlipidemia, arterioesclerosis, ateroesclerosis, vasculopatia periferica, dislipidemia, entre otras enfermedades.
BR112012008317A2 (pt) produto de liberação sustentada compreendendo uma combinação de uma amina não-opioide e uma droga anti-inflamatória não-esteroidal
BRPI0813306A2 (pt) composto, composição farmacêutica, método para produzir a inibição de uma cisteína protease em um mamífero, e, uso de um composto.
DOP2010000134A (es) Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos
CL2007003832A1 (es) Compuestos derivados de azaespiro; procedimiento de preparacion; composicion farmaceutica; y su uso para prevenir y tratar ansiedad, trastornos depresivos, entre otras enfermedades.
CL2009001484A1 (es) Sal glicinato de metformina; composición farmacéutica que comprende la sal; y su uso para tratar la hiperglicemia.
CR10454A (es) Composiciones farmaceuticas novedosas de baja dosis que comprenden nimesulida , preparacion y uso de las mismas
BRPI0707704A8 (pt) derivados de antranilamida / 2-amino-heteroareno carboxamida
CL2007000918A1 (es) Compuestos derivados de enfumafungina, inhibidores de (1,3)-beta-d-glucanosintetasa; composicion farmaceutica; y uso para tratar una infeccion fungica.
BRPI0914371A2 (pt) "composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo, e produto de combinação"
UY30652A1 (es) N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)piperidin-4-ilideno)metil)benzamida
BRPI0516464B8 (pt) método para a preparação de um produto farmacêutico
CU20090039A7 (es) 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridina-2-carboxamida monohidrato
DOP2009000045A (es) 4-[4-({[4-cloro-3-(trifluorometil) fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridina-2-carboxamida monohidrato
AR067351A1 (es) Combinacion de picotamida con nafronil
EA200701180A1 (ru) Способ и промежуточные продукты для получения канфосфамида и его солей, фармацевтические композиции, содержащие некоторые промежуточные продукты и их применение в качестве противораковых средств